UCB Announces the Approval of CIMZIA(R) (certolizumab pegol) for Moderate-to-Severe Plaque Psoriasis, Representing an Important New Option for Patients in the U.S.

The U.S. Food and Drug Administration's (FDA) approval of CIMZIA® (certolizumab pegol) for use in moderate-to-severe plaque psoriasis marks the entry of UCB into immuno-dermatology CIMZIA Phase 3 psoriasis studies demonstrated significant and clinic... Biopharmaceuticals, Dermatology, FDA UCB , CIMZIA, certolizumab pegol, psoriasis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news